Format

Send to

Choose Destination
Lancet Oncol. 2016 Jul;17(7):860-862. doi: 10.1016/S1470-2045(16)30203-0. Epub 2016 Jun 6.

Combined BRAF and MEK inhibition in BRAF-mutant NSCLC.

Author information

1
Department of Medical Oncology, Austin Health, Olivia Newton- John Cancer and Wellness Centre, VIC 3084, Australia; University of Melbourne, VIC, Australia.
2
Department of Medical Oncology, Austin Health, Olivia Newton- John Cancer and Wellness Centre, VIC 3084, Australia; University of Melbourne, VIC, Australia; Thoracic Alliance for Cancer Trials, Milton, QLD, Australia. Electronic address: paul.mitchell@austin.org.au.
PMID:
27283865
DOI:
10.1016/S1470-2045(16)30203-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center